Luly Jay R. (CIK 1571211) reported 8 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-02-13). Recent activity: Buy ENTA (4,800 shares), Buy ENTA (15,200 shares), Sell ENTA (6,155 shares), Sell ENTA (4,743 shares), Sell ENTA (1,885 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-13 | ENANTA PHARMACEUTICALS INC (ENTA) | President and CEO | Buy | 4,800 | $0 |
| 2026-02-13 | ENANTA PHARMACEUTICALS INC (ENTA) | President and CEO | Buy | 15,200 | $0 |
| 2026-02-13 | ENANTA PHARMACEUTICALS INC (ENTA) | President and CEO | Sell | 6,155 | $87,709 |
| 2025-12-05 | ENANTA PHARMACEUTICALS INC (ENTA) | President and CEO | Sell | 4,743 | $67,493 |
| 2025-12-03 | ENANTA PHARMACEUTICALS INC (ENTA) | President and CEO | Sell | 1,885 | $26,616 |
| 2025-02-14 | ENANTA PHARMACEUTICALS INC (ENTA) | President and CEO | Buy | 25,500 | $0 |
| 2025-02-14 | ENANTA PHARMACEUTICALS INC (ENTA) | President and CEO | Sell | 7,484 | $41,836 |
| 2025-02-12 | ENANTA PHARMACEUTICALS INC (ENTA) | President and CEO | Buy | 45,000 | $256,050 |
Source: SEC Form 4 filings · as of 2026-02-13